Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
MINNEAPOLIS, Feb. 02, 2016 -- Urologix, Inc. (OTC Pink:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today that as of the close of business on January 29, 2015 substantially all of the operating assets of Urologix, Inc. including the Urologix name were surrendered to a secured creditor and subsequently purchased by a private company to partially address the secured debt owed to the secured creditor. The sale of Urologix’s operating assets was contemplated by a forbearance agreement entered into with the secured creditor on December 7, 2015. The buyer will operate the existing business through an entity named “Urologix, LLC.”
The transaction will enable Urologix, LLC to provide urology customers and their patients with both Cooled ThermoTherapy and Prostiva RF Therapy products and services to treat BPH in the comfortable setting of a urologist’s office.
Concurrent with these events, Urologix, Inc. was renamed 21st North Inc. Immediately following the transaction, 21st North Inc. has no operations and has commenced an orderly wind down. Accordingly, 21st North intends to submit a proposal to its shareholders in the ensuing weeks to approve a plan of dissolution. The Company will not be making liquidating distributions to shareholders at any time.
Contact Information: Greg Fluet [email protected]
